Project Grant K01DK144664
Award Date 9/15/25
Completion Date 7/31/28
Dollars Obligated $139K
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Missouri, USA
Similar Awards
- This federal Project Grant award of $208,428, provided by the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research), aims to enhance the safety and efficacy of stem cell-derived islet transplantation for treating type 1 diabetes. The key objectives are to improve the survival and engraftment of the transplanted cells, enable long-term insulin independence, and develop safety mechanisms to retrieve the graft...
- This $3,140,632 federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research program) aims to elucidate the mechanisms underlying human endocrine lineage commitment and harness this knowledge to improve strategies for beta cell replacement in diabetes treatment. The 4-year project, awarded to the Regents of the University of California, San Francisco, seeks to enhance the...
- This $681,562 Project Grant awarded by the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research) aims to investigate approaches for enhancing the metabolic maturity and functionality of human pluripotent stem cell-derived islet organoids, with the goal of improving their survival and efficacy for transplantation as a treatment for type 1 diabetes. The research will examine the use of pharmacological agents...
- This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $199,258 to The Leland Stanford Junior University to conduct research aimed at advancing cell-based therapies for Type 1 Diabetes Mellitus (T1D). The key objectives are to: 1) establish effective, non-toxic strategies to induce immune tolerance toward donor tissues for islet cell...
- This $146,829 Project Grant awarded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), aims to investigate the molecular mechanisms by which the bacterial protein BEFA (beta-cell expansion factor A) induces the proliferation and metabolic maturation of pancreatic beta cells. The research, conducted at the University of Oregon, utilizes single-cell imaging, genetic...
- This $2,263,983 Project Grant award, funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), supports research to develop "engineered regulatory T cells (Tregs)" as an immunotherapy for type 1 diabetes. The central goal is to create antigen-specific Tregs that can more effectively suppress the autoimmune destruction of insulin-producing beta cells. The research...
- This Cooperative Agreement award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $1,108,154 to develop a stem cell-based multi-cellular platform that integrates diverse types of immune cells with stem cell-derived islets. The goal is to create an improved preclinical research model to accelerate the development of therapeutic interventions for Type 1...
- This federal Project Grant award of $801,662, provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), supports research by the Scripps Research Institute to investigate the early phase of type 1 diabetes. The key objectives are to characterize the antigen-presenting cells associated with pancreatic islets during the pre-diabetic stage in mice, using advanced techniques...
- The University of California, Davis received a $126,480 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847) to conduct research on the role of the signaling protein 14-3-3-z in regulating the crosstalk between pancreatic islet cells. The research aims to define a new pathway regulating 14-3-3-z expression in beta cells and investigate how this impacts alpha cell function and glucose-stimulated insulin secretion. This project is expected...
- This federal Project Grant award of $2,390,830 from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847) aims to develop scalable and transplantable pancreatic islet organoids with engineered oxygenation. The 4-year project, awarded on September 1, 2025, will be carried out by the University of California, San Francisco. The research seeks to create an islet-supportive microenvironment to improve islet engraftment efficiency for Type 1 diabetes patients undergoing...
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847) provides $138,753 to The Washington University to support research on cytoskeletal regulation of gut tube organogenesis and subsequent maturation of stem cell-derived islets. The goal is to enable a cell-based therapy to become a viable and widely-used treatment option for type 1 diabetes, which results from the autoimmune destruction of insulin-producing beta cells. The research will investigate new aspects of beta cell development and maturation, with the aim of generating an unlimited supply of highly functional islets for cell therapy. The award period runs from Sep 15, 2025 to Jul 31, 2028.
Generated 10/21/25, 6:28 AM
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $138.8k | 9/11/25 |